部分缓解的发生和持续时间对1型糖尿病短期代谢控制的影响:DIABHONEY儿科研究

IF 3.9 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Therapeutic Advances in Endocrinology and Metabolism Pub Date : 2023-01-01 DOI:10.1177/20420188221145550
Laure Boutsen, Elise Costenoble, Olivier Pollé, Kezban Erdem, Céline Bugli, Philippe A Lysy
{"title":"部分缓解的发生和持续时间对1型糖尿病短期代谢控制的影响:DIABHONEY儿科研究","authors":"Laure Boutsen,&nbsp;Elise Costenoble,&nbsp;Olivier Pollé,&nbsp;Kezban Erdem,&nbsp;Céline Bugli,&nbsp;Philippe A Lysy","doi":"10.1177/20420188221145550","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the residual effect of partial remission (PR) on immediate post-PR glycemic control according to its occurrence and duration in a cohort of children with type 1 diabetes mellitus (T1DM).</p><p><strong>Patients and methods: </strong>Values of glycemic control parameters [i.e. HbA<sub>1C</sub>, insulin dose-adjusted hemoglobin A<sub>1C</sub> (IDAA<sub>1C</sub>), glycemic target-adjusted HbA<sub>1C</sub> (GTAA<sub>1C</sub>)] and data from glucose monitoring devices from 189 pediatric patients with new-onset type 1 diabetes were collected retrospectively from 24 months. Patients were characterized according to their remission status (PR<sup>+</sup> and PR<sup>-</sup>). PR<sup>+</sup> patients were subdivided into three subgroups regarding PR duration [i.e. short (⩾3-⩽6 months), intermediate (>6-⩽12 months), and long PR (>12-⩽14 months)]. We compared glycemic control data from each PR<sup>+</sup> subgroup at +6 and +12 months post-PR with PR<sup>-</sup> patients at the same postdiagnosis time. Second, PR<sup>+</sup> subgroups were compared with each other.</p><p><strong>Results: </strong>PR<sup>+</sup> patients showed improved glycemic control (i.e. HbA<sub>1C</sub>, IDAA<sub>1C</sub>, and GTAA<sub>1C</sub>) at + 6 months post-PR when compared with nonremitters (PR<sup>-</sup>), independently of the PR duration subgroups (p < 0.05). Interestingly, patients in long PR<sup>+</sup> subgroup exhibited higher positive residual effect than short PR<sup>+</sup> subgroup with lower GTAA<sub>1C</sub> scores (p = 0.02), better time in range (TIR) (p = 0.003), less time in hypoglycemia (10.45 <i>versus</i> 16.13%, p = 0.03) and less glycemic variability (83.1 mg/dl <i>versus</i> 98.84 mg/dl, p = 0.03). No significant differences were found for glucose control between PR<sup>+</sup> and PR<sup>-</sup> patients at +12 months post-PR.</p><p><strong>Conclusion: </strong>This study supports the positive impact of PR occurrence and duration on short-term metabolic control (better HbA<sub>1C</sub> levels, IDAA<sub>1C</sub> and GTAA<sub>1C</sub> scores, TIR, and less glycemic variability) with the residual effect increasing according to PR duration.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":null,"pages":null},"PeriodicalIF":3.9000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e8/a6/10.1177_20420188221145550.PMC9869204.pdf","citationCount":"0","resultStr":"{\"title\":\"Influence of the occurrence and duration of partial remission on short-term metabolic control in type 1 diabetes: the DIABHONEY pediatric study.\",\"authors\":\"Laure Boutsen,&nbsp;Elise Costenoble,&nbsp;Olivier Pollé,&nbsp;Kezban Erdem,&nbsp;Céline Bugli,&nbsp;Philippe A Lysy\",\"doi\":\"10.1177/20420188221145550\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To evaluate the residual effect of partial remission (PR) on immediate post-PR glycemic control according to its occurrence and duration in a cohort of children with type 1 diabetes mellitus (T1DM).</p><p><strong>Patients and methods: </strong>Values of glycemic control parameters [i.e. HbA<sub>1C</sub>, insulin dose-adjusted hemoglobin A<sub>1C</sub> (IDAA<sub>1C</sub>), glycemic target-adjusted HbA<sub>1C</sub> (GTAA<sub>1C</sub>)] and data from glucose monitoring devices from 189 pediatric patients with new-onset type 1 diabetes were collected retrospectively from 24 months. Patients were characterized according to their remission status (PR<sup>+</sup> and PR<sup>-</sup>). PR<sup>+</sup> patients were subdivided into three subgroups regarding PR duration [i.e. short (⩾3-⩽6 months), intermediate (>6-⩽12 months), and long PR (>12-⩽14 months)]. We compared glycemic control data from each PR<sup>+</sup> subgroup at +6 and +12 months post-PR with PR<sup>-</sup> patients at the same postdiagnosis time. Second, PR<sup>+</sup> subgroups were compared with each other.</p><p><strong>Results: </strong>PR<sup>+</sup> patients showed improved glycemic control (i.e. HbA<sub>1C</sub>, IDAA<sub>1C</sub>, and GTAA<sub>1C</sub>) at + 6 months post-PR when compared with nonremitters (PR<sup>-</sup>), independently of the PR duration subgroups (p < 0.05). Interestingly, patients in long PR<sup>+</sup> subgroup exhibited higher positive residual effect than short PR<sup>+</sup> subgroup with lower GTAA<sub>1C</sub> scores (p = 0.02), better time in range (TIR) (p = 0.003), less time in hypoglycemia (10.45 <i>versus</i> 16.13%, p = 0.03) and less glycemic variability (83.1 mg/dl <i>versus</i> 98.84 mg/dl, p = 0.03). No significant differences were found for glucose control between PR<sup>+</sup> and PR<sup>-</sup> patients at +12 months post-PR.</p><p><strong>Conclusion: </strong>This study supports the positive impact of PR occurrence and duration on short-term metabolic control (better HbA<sub>1C</sub> levels, IDAA<sub>1C</sub> and GTAA<sub>1C</sub> scores, TIR, and less glycemic variability) with the residual effect increasing according to PR duration.</p>\",\"PeriodicalId\":22998,\"journal\":{\"name\":\"Therapeutic Advances in Endocrinology and Metabolism\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e8/a6/10.1177_20420188221145550.PMC9869204.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Endocrinology and Metabolism\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/20420188221145550\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Endocrinology and Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20420188221145550","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

目的:根据部分缓解(PR)在1型糖尿病(T1DM)患儿队列中的发生情况和持续时间,评价部分缓解(PR)对术后即刻血糖控制的剩余效应。患者与方法:回顾性收集189例新发1型糖尿病患儿24个月的血糖控制参数[即HbA1C、胰岛素剂量调节血红蛋白A1C (IDAA1C)、血糖靶调节HbA1C (GTAA1C)]值及血糖监测设备数据。根据患者的缓解状态(PR+和PR-)进行特征描述。PR+患者根据PR持续时间细分为三个亚组[即短(大于或等于3-≥6个月),中间(大于或等于6-≥12个月)和长PR(大于或等于12-≥14个月)]。我们比较了每个PR+亚组在PR后+6个月和+12个月与PR-患者在相同诊断后时间的血糖控制数据。其次,比较PR+亚组间的差异。结果:PR+患者在PR后6个月与非缓解者(PR-)相比,血糖控制(即HbA1C, IDAA1C和GTAA1C)得到改善,独立于PR持续时间亚组(p +亚组比短PR+亚组表现出更高的阳性残余效应,GTAA1C评分较低(p = 0.02),范围时间(TIR)较好(p = 0.003),低血糖时间较短(10.45%对16.13%,p = 0.03),血糖变变性较小(83.1 mg/dl对98.84 mg/dl, p = 0.03)。PR+和PR-患者在PR后12个月的血糖控制无显著差异。结论:本研究支持PR的发生和持续时间对短期代谢控制(更好的HbA1C水平、IDAA1C和GTAA1C评分、TIR、更小的血糖变异性)的积极影响,且残留效应随PR持续时间的增加而增加。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Influence of the occurrence and duration of partial remission on short-term metabolic control in type 1 diabetes: the DIABHONEY pediatric study.

Objective: To evaluate the residual effect of partial remission (PR) on immediate post-PR glycemic control according to its occurrence and duration in a cohort of children with type 1 diabetes mellitus (T1DM).

Patients and methods: Values of glycemic control parameters [i.e. HbA1C, insulin dose-adjusted hemoglobin A1C (IDAA1C), glycemic target-adjusted HbA1C (GTAA1C)] and data from glucose monitoring devices from 189 pediatric patients with new-onset type 1 diabetes were collected retrospectively from 24 months. Patients were characterized according to their remission status (PR+ and PR-). PR+ patients were subdivided into three subgroups regarding PR duration [i.e. short (⩾3-⩽6 months), intermediate (>6-⩽12 months), and long PR (>12-⩽14 months)]. We compared glycemic control data from each PR+ subgroup at +6 and +12 months post-PR with PR- patients at the same postdiagnosis time. Second, PR+ subgroups were compared with each other.

Results: PR+ patients showed improved glycemic control (i.e. HbA1C, IDAA1C, and GTAA1C) at + 6 months post-PR when compared with nonremitters (PR-), independently of the PR duration subgroups (p < 0.05). Interestingly, patients in long PR+ subgroup exhibited higher positive residual effect than short PR+ subgroup with lower GTAA1C scores (p = 0.02), better time in range (TIR) (p = 0.003), less time in hypoglycemia (10.45 versus 16.13%, p = 0.03) and less glycemic variability (83.1 mg/dl versus 98.84 mg/dl, p = 0.03). No significant differences were found for glucose control between PR+ and PR- patients at +12 months post-PR.

Conclusion: This study supports the positive impact of PR occurrence and duration on short-term metabolic control (better HbA1C levels, IDAA1C and GTAA1C scores, TIR, and less glycemic variability) with the residual effect increasing according to PR duration.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Therapeutic Advances in Endocrinology and Metabolism
Therapeutic Advances in Endocrinology and Metabolism Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
7.70
自引率
2.60%
发文量
42
审稿时长
8 weeks
期刊介绍: Therapeutic Advances in Endocrinology and Metabolism delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of endocrinology and metabolism.
期刊最新文献
Analyzing and evaluating the prevalence and metabolic profile of lean NAFLD compared to obese NAFLD: a systemic review and meta-analysis. Glycaemic outcomes in people living with diabetes under 65 and over 65 years old using an intermittently scanned continuous glucose monitoring system. ANDROID and A/G ratio are correlated with sarcopenia among type 2 diabetes patients. Diabetes and gout: another role for SGLT2 inhibitors? Chronic kidney disease combined with metabolic syndrome is a non-negligible risk factor
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1